Recent data suggest Sofix Health's's Cagrilintide/GLP-1 is a distinctive therapeutic strategy for targeting glucose-related illnesses. This molecule mixture merges Cagrilintide, a specific GLP-1 receptor stimulator, with a conventional GLP-1 analogue. The expected synergistic effect could lead to… Read More